

## **Supplemental Methods**

### **Details of the participants at each institute**

The HC individuals had no history of psychiatric illness or substance abuse. The exclusion criteria for all participants were a history of head trauma, neurological illness, or serious medical or surgical illness. The details of each site were as follows:

#### 1) Institute of Psychiatry, Psychology and Neuroscience (IoPPN)

Subjects at ultra-high risk (UHR) for psychosis and healthy controls (HC) were recruited between December 2009 and September 2011. UHR subjects were referred to IoPPN from the Outreach and Support in South London (OASIS) program. UHR was defined as the presentation of one or more of the following: 1) attenuated psychotic symptoms, 2) brief limited intermittent psychotic episode, and/or 3) genetic risk and deterioration syndrome. Comorbidities in individuals at UHR included past or current depression (n = 13), personality disorders (n = 5), anxiety disorders (n = 5), and body dysmorphic disorder (n = 1). Among them, ten UHR individuals had comorbidities other than schizophrenia spectrum or mood disorders. The Comprehensive Assessment of At-Risk Mental States (CAARMS) was used for diagnostic purposes in the intake assessment and when performing scans for the assessment of symptom severity. The latter is presented in [Table 1](#) of the main text. Details of the demographic and clinical data are presented in [Table 1](#) in the main text. HC subjects had no first-degree relatives with psychotic disorders.

#### 2) Johns Hopkins University (JHU)

Patients with first-episode psychosis (FEP) and HC were recruited between January 2014 and November 2015. The diagnosis was made based on the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). FEP included schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis NOS, and depression or bipolar disorder with hallucinations or delusions. Six FEP patients had comorbidities other than schizophrenia spectrum or mood disorders: childhood or current diagnosis of autism (n = 2), attention-deficit/hyperactivity disorder (n = 2), past history of anorexia nervosa (n = 1), and trichotillomania (n = 1). Forty-one patients were administered antipsychotics, four were unmedicated, and six were medicated but without information on the current dose. HC subjects had no first-degree relatives with psychotic disorders. Demographic and clinical data are shown in [Supplemental Table 1](#).

#### 3) Kanazawa Medical University (KMU)

FEP and chronic psychosis (ChrP) patients, as well as HC, were recruited between November 2011 and August 2018. All patients were diagnosed as schizophrenia using SCID without

comorbidity with other Axis I disorders. No patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 2](#).

#### 4) Kyoto University (Kyoto)

ChrP and HC participants were recruited between October 2010 and June 2013. The diagnoses were made based on the SCID. ChrP included schizophrenia, schizoaffective disorder, and schizophreniform disorder. Patients were not comorbid with any other Axis I disorders. All patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 3](#).

#### 5) Osaka University (OSK2 and OSK3)

Patients with FEP and ChrP, as well as HC, were recruited between August 2011 and August 2013 (OSK2), and between February 2014 and January 2017 (OSK3). The diagnoses were confirmed using the SCID. All patients were diagnosed with schizophrenia, schizophreniform disorder, or brief psychotic disorder without comorbidity with other Axis I disorders. No patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are shown in [Supplemental Table 4 and 5](#).

#### 6) The University of Tokyo (Tokyo)

Patients with FEP and ChrP, as well as HC, were recruited between June 2014 and February 2019. All patients were diagnosed with schizophrenia without comorbidity with other Axis I disorders using SCID. All patients were administered antipsychotics. The details are shown in [Supplemental Table 6](#).

#### 7) University of Toyama (TYM)

Patients with FEP and ChrP, as well as HC, were recruited between April 2015 and May 2017. All patients were diagnosed with schizophrenia without comorbidity with other Axis I disorders based on the SCID. None of the patients were administered antipsychotics. HC subjects had no first-degree relatives with psychotic disorders. The details are presented in [Supplemental Table 7](#).

## **Supplemental Results**

### **No effects of comorbidity on the group difference results**

In the significant group comparison results of the within-network analysis of UHR, the cluster value of the ACC of the SN-ACC did not differ between individuals without comorbidity (n = 19)

and those with comorbidity ( $n = 10$ ) ( $p = 0.59$ , corrected for contrast). The cluster value of the right thalamus of BGN-MbThal did not differ between FEP patients without comorbidity ( $n = 45$ ) and those with comorbidity ( $n = 6$ ) ( $p = 0.55$ , corrected for contrast). The transition rate of the ELA in FEP did not differ ( $p = 0.36$ , corrected for contrast).

### **No effects of smoking on the group difference results**

In the significant group comparison results of the within-network analysis of UHR, the cluster value of the ACC of the SN-ACC did not differ between nonsmokers ( $n = 10$ ) and smokers ( $n = 16$ ) ( $p = 0.48$ , corrected for contrast). The cluster value of the right thalamus of the BGN-MbThal of the FEP group did not differ between non-smokers ( $n = 57$ ) and smokers ( $n = 16$ ) ( $p = 0.59$ , corrected for contrast). The transition rate of the ELA in FEP did not differ ( $p = 0.65$ , corrected for contrast).

### **No effects of substance use on the group difference and correlation results**

In the significant group difference result of the within-network analysis of UHR, the cluster value of the ACC of the SN-ACC did not differ between non-users (25) and users (4) ( $p = 0.33$ , corrected for contrast). The cluster value of the right thalamus of the BGN-MbThal of FEP at the JHU site did not differ between non-users ( $n = 37$ ) and users ( $n = 11$ ) ( $p = 0.44$ , corrected for contrast). The transition rate between the two brain states did not differ between the non-users and users ( $p = 0.31$ , corrected for contrast).

In the significant correlation analysis results for FEP, we did not find a significant interaction between substance use (34 non-users and 10 users) and PANSS on the mean cluster value of the MTLN ( $p = 0.18$ , corrected for contrast), or on the connectivity between the MTLN and BGN-MbThal ( $p = 0.14$ , corrected for contrast).

### **Exclusion of the patient of the highest connectivity value**

We supplementarily excluded the patient with FEP with the highest connectivity values from correlational analyses. The cluster value of the bilateral hippocampus of the MTLN remained significantly correlated with the PANSS positive scale ( $p < 0.001$ , corrected for contrast). The positive correlation between the PANSS positive scale and the connectivity between the MTLN and BGN-MbThal also remained significant ( $p = 0.02$ , corrected for contrast).

For the interaction results with medication and psychosis type, we performed this exclusion analysis for all six sites, but not for the JHU site because of the small sample size. The significant interaction between medication and the PANSS positive scale on the within-network connectivity of the MTLN turned into trend-level ( $p = 0.053$ , corrected for contrast). The

significant interaction between medication and the PANSS positive scale on the connectivity between the MTLN and BGN-MbThal also turned into trend level ( $p = 0.058$ , corrected for contrast).

The significant interaction between psychosis type and the PANSS positive scale on the within-network connectivity of the MTLN disappeared ( $p = 0.4$ , corrected for contrast). The significant interaction between psychosis type and the PANSS positive scale on the connectivity between the MTLN and BGN-MbThal also disappeared for all six sites ( $p = 0.5$ , corrected for contrast).

**Supplemental Table 1. Demographic and clinical data of individuals recruited at Johns Hopkins University (JHU)**

	HC (73)	FEP (51)	Statistics	DoF	P
Age, mean years (SD)	24.1 (3.7)	22.6 (4.7)	t = 1.85	90.5	0.07
Age range, years	18-34	15-34			
Sex (female/male)	36/37	17/34	Chi-square = 3.1	1	0.1*
Ethnicity			Chi-square = 2.7	5	0.75
African	43	26			
Caucasian	26	19			
Asian	2	3			
Hispanic	0	1			
Mixed	1	1			
Unknown	1	1			
Education (year)	14.7 (2.1)	13.2 (3.1)	t = 3.0	82.1	0.004
Smoking (yes/no)	4/69	16/35	Chi-square = 14.9	1	< 0.001*
Cannabis use (yes/no)	2/71	11/37	Chi-square = 12.3	1	0.001*
Duration of illness (years)		1.3 (0.9)			
SAPS total		15.6 (20.0)			
SANS total		30.7 (21.9)			
PANSS positive **		13.0 (4.2)			
CP eq.		470.1 (321.6)			
tSNR	5065.2 (1563.0)	5065.0 (1963.3)	t = 0.001	122	1.00

\* Fisher's exact test.

\*\* Converted from SAPS.

### Abbreviations

CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; tSNR, temporal signal/noise ratio.

**Supplemental Table 2. Demographic and clinical data of individuals recruited at Kanazawa Medical University (KMU)**

	HC (15)	FEP (4) & ChrP (4)	Statistics	DoF	P
Age, mean years (SD)	29.7 (8.8)	32.0 (12.2)	t = -0.53	21	0.6
Age range, years	19-49	20-51			
Sex (female/male)	10/5	2/6	Chi-square = 3.6	1	0.09*
Ethnicity	All Japanese	All Japanese			
Education (year)	16.5 (1.6)	13.1 (1.8)	t = 4.6	20	< 0.001
Smoking	Not available	Not available			
Substance use	All negative	All negative			
Duration of illness (years)		3.1 (3.7)			
PANSS positive		17.4 (4.9)			
PANSS negative		18.8 (5.7)			
PANSS general		30.1 (6.7)			
CP eq		0			
tSNR	1866.9 (373.6)	2004.3 (493.5)	t = -0.75	21	0.46

\* Fisher's exact test.

#### **Abbreviations**

ChrP, chronic schizophrenia; CP eq, chrolpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 3. Demographic and clinical data of individuals recruited at Kyoto University (Kyoto)**

	HC (41)	ChrP (46)	Statistics	DoF	P
Age, mean years (SD)	36.3 (6.7)	39.0 (9.2)	t = -1.57	82.1	0.12
Age range, years	30-57	24-57			
Sex (female/male)	11/30	21/25	Chi-square = 3.3	1	0.08*
Ethnicity	All Japanese	All Japanese			
Education (years)	16.7 (2.2)	14.1 (2.2)	t = 5.26	81	< 0.001
Smoking (yes/no)	5/31	9/34	Chi-square = 0.67	1	0.56*
Substance use	All negative	All negative			
Duration of illness (years)		14.3 (7.8)			
PANSS positive		14.6 (5.1)			
PANSS negative		15.7 (5.6)			
PANSS general		29.6 (9.8)			
CP eq		591.8 (480.1)			
tSNR	1423.0 (334.5)	1681.7 (551.9)	t = -2.68	75.3	0.009

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chrolpromazine equivalent; DoF, degree of freedom; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 4. Demographic and clinical data of individuals recruited at OSAKA University MRI2 (OSK2)**

	HC (17)	FEP (2) & ChrP (7)	Statistics	DoF	P
Age, mean years (SD)	32.4 (15.4)	33.6 (16.2)	t = -.186	24	0.85
Age range, years	20-64	20-64			
Sex (female/male)	12/5	6/3	Chi-square = 0.042	1	1.00*
Ethnicity	All Japanese	All Japanese			
Education (years)	14.7 (2.4)	13.2 (1.9)	t = 1.54	24	0.14
Smoking (yes/no)	(0/17)	(2/7)			
Substance use	All negative	All negative			
Duration of illness (years)		8.2 (7.3)			
PANSS positive		18.7 (4.9)			
PANSS negative		20.3 (5.9)			
PANSS general		45.4 (9.8)			
CP eq		0			
tSNR	7950.8 (1176.9)	8559.7 (872.1)	t = -1.36	24	0.19

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.



**Supplemental Table 5. Demographic and clinical data of individuals recruited at OSAKA University MRI3 (OSK3)**

	HC (35)	FEP (7) & ChrP (14)	Statistics	DoF	P
Age, mean years (SD)	30.5 (11.3)	27.7 (8.0)	t = 1.01	54	0.32
Age range, years	18-66	16-43			
Sex (female/male)	19/16	11/10	Chi-square = 0.19	1	1.00*
Ethnicity	All Japanese	All Japanese			
Education (years)	14.9 (2.4)	13.4 (2.7)	t = 2.15	54	0.04
Smoking (yes/no)	5/30	0/21			
Substance use	All negative	All negative			
Duration of illness (years)		5.8 (5.6)			
PANSS positive		20.1 (4.2)			
PANSS negative		21.9 (4.3)			
PANSS general		47.2 (10.8)			
CP eq		0			
tSNR	17285.8 (2516.7)	20959.8 (4610.9)	t = -3.36	27.3	0.002

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 6. Demographic and clinical data of individuals recruited at the University of Tokyo (Tokyo)**

	HC (63)	FEP (14) & ChrP (26)	Statistics	DoF	P
Age, mean years (SD)	38.7 (8.2)	28.9 (10.0)	t = 5.43	101	< 0.001
Age range, years	25-59	16-52			
Sex (female/male)	37/26	17/23	Chi-square = 2.58	1	0.16*
Ethnicity	All Japanese	All Japanese			
Education (years)	15.8 (2.3)	13.4 (2.4)	t = 5.14	101	< 0.001
Smoking (yes/no)	6/57	4/31	Chi-square = 0.09	1	0.74*
Substance use	All negative	All negative			
Duration of illness (years)		8.6 (8.6)			
PANSS positive		16.2 (4.9)			
PANSS negative		19.0 (6.7)			
PANSS general		33.6 (7.7)			
CP eq		546.5 (431.3)			
tSNR	19682.8 (4260.1)	18862.8 (3209.5)	t = 1.04	101	0.3

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 7. Demographic and clinical data of individuals recruited at the University of Toyama (TYM)**

	HC (10)	FEP (3) & ChrP (2)	Statistics	DoF	P
Age, mean years (SD)	25.30 (5.67)	28.20 (7.91)	t = -.82	13	0.43
Age range, years	21-37	21-39			
Sex (female/male)	6/4	2/3	Chi-square = 0.54	1	0.61*
Ethnicity	All Japanese	All Japanese			
Education (years)	16.5 (1.6)	14.4 (1.7)	t = 2.38	13	0.03
Smoking	Not available	Not available			
Substance use	All negative	All negative			
Duration of illness (years)		3.2 (3.8)			
PANSS positive		15.8 (3.6)			
PANSS negative		17.0 (7.6)			
PANSS general		35.8 (8.4)			
CP eq		0			
tSNR	2610.6 (340.8)	2885.9 (512.3)	t = -1.25	13	0.23

\* Fisher's exact test

### Abbreviations

ChrP, chronic schizophrenia; CP eq, chlorpromazine equivalent; DoF, degree of freedom; FEP, first-episode psychosis; HC, healthy controls; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal/noise ratio.

**Supplemental Table 8. Scanning parameters at each site**

	IoPPN	JHU	KMU	Kyoto	OSK2	OSK3	Tokyo	TYM
Vendor	Siemens	Philips	Siemens	Siemens	GE	GE	GE	Siemens
Type	TimTRIO	Achieva	TimTRIO	TRIO	Signa HDxt	DISCOVERY MR750	DISCOVERY MR750w	Verio
Head coil (channel)	32	32	32	8	8	8	24	12
Magnetic field	3T (Tesla)	3T	3T	3T	3T	3T	3T	3T
T1-weighted image								
Sequence	MP2RAGE	MPRAGE	MPRAGE	MPRAGE	FSPGR	FSPGR	FSPGR	MPRAGE
Repetition time (ms)	5000	6.8	1420	2000	7.2	8.16	7.65	2300
Echo time (ms)	2.96	3.1	2.08	4.38	2.9	3.17	3.1	2.9
Inversion time (ms)	700 & 2500	845	800	990	400	400	400	900
Flip angle	4	8	9	8	11	11	11	9
Resolution (x/y/z in mm)	1/1/1	1.2/1/1	0.9/0.9/0.9	0.94/0.94/1	1/0.94/0.94	1.2/1/1	1/1/1.2	1.2/1/1
RsfMRI								
Eyes	Open	No instruction	Open/ no instruction	Open	Closed	Open	Open	Open
Sequence	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI	GRE-EPI
Phase encoding direction	A-P	P-A	A-P	A-P	P-A	P-A	P-A	P-A
Repetition time (ms)	2000	2000	2000	2000	2000	2500	2500	2500
Echo time (ms)	31	30	30	30	30	30	30	30
Flip angle	80	75	90	90	90	80	80	80
Resolution (mm, x/y/z)	3.5/3.5/3	3/3/3	3.75/3.75/5	4/4/4	3.44/3.44/3.5	3.31/3.31/3.2	3.31/3.31/3.2	3.31/3.31/3.2
Slice order	Interleaved	Ascending	Interleaved	Interleaved	Interleaved	Ascending	Ascending	Ascending
Slice gap (mm)	0	1	0	0	0	0.8	0.8	0.8
volumes	150	210	150	180	150	240	244	240

## **Abbreviations**

FSPGR, fast spoiled gradient echo; GRE-EPI, gradient echo echo-planar imaging; IoPPN, Institute of Psychiatry, Psychology and Neuroscience, King's College London; JHU, Johns Hopkins University; KMU, Kanazawa Medical University; Kyoto, Kyoto University; MPRAGE, magnetization-prepared rapid gradient echo; MP2RAGE, magnetization-prepared 2 rapid acquisition gradient echoes; OSK2, Osaka University MRI2; OSK3, Osaka University MRI3; RsfMRI, resting-state functional magnetic resonance imaging; Tokyo, The University of Tokyo; TYM, University of Toyama.


**Supplemental Table 9. Thresholds of ICA-denoising at each site**

Threshold	IoPPN	JHU	KMU	Kyoto	OSK2	OSK3	Tokyo	TYM
HF	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.5
NB	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.6
SL	2	2	2	2	2	2	2	2

**Abbreviations**

HF, high-frequency power ratio; IoPPN, Institute of Psychiatry, Psychology and Neuroscience, King's College London; JHU, Johns Hopkins University; KMU, Kanazawa Medical University; Kyoto, Kyoto University; NB, non-gray matter index; OSK2, Osaka University MRI2; OSK3, Osaka University MRI3; SL, slice dependency; Tokyo, The University of Tokyo; TYM, University of Toyama.

**Supplemental Figure 1. Reduced within-network connectivity in UHR, FEP, and ChrP patients**




UHR (n=29) patients were compared to matched HC (n=25), FEP (n=81) with matched HC (n=109), and ChrP (n= 99) with matched HC (n=145). Yellow and \*\*\* indicate a significant reduction of connectivity in patients at  $p < 0.05$ , corrected for voxels (threshold-free cluster enhancement), two contrasts, and five networks. Orange and \*\* indicate trend-level significance at  $p < 0.1$ , corrected for voxel, contrast, and network. Red and \* indicate significance at  $p < 0.05$ , corrected for voxel and contrast. Light blue indicates the NOIs.

**Abbreviations**

ACC, anterior cingulate cortex; BGN, basal ganglia network; ChrP, chronic schizophrenia; FEP, first-episode psychosis; HC, healthy controls; Ins, insula; MbThal, midbrain and thalamus; MTLN, medial temporal lobe network; NOI, network of interest; SN, salience network; Str, striatum; UHR, ultra-high-risk.



**Supplemental Figure 2. Correlational analysis results**



**a) Positive correlation between PANSS positive scale and connectivity in FEP (n=76)**

Yellow and \*\*\* indicate significance at  $p < 0.05$ , corrected for voxels using threshold-free cluster enhancement, two contrasts, and five networks. Orange indicates trend-level significance at  $p < 0.1$ , corrected for voxel, contrast, and network. Red and \* indicate significance at  $p < 0.05$ , corrected for voxel and contrast. Light blue indicates the NOIs.


**b) Positive correlation between PANSS positive scale and static between-network connectivity in FEP (n=76).**

\*\*\* indicates significance at  $p < 0.05$ , corrected for two contrasts and 10 NOI-pairs. \* indicates significance at  $p < 0.05$ , corrected for contrast. The PANSS scores and connectivity values were controlled for age, sex, and tSNR.

**Abbreviations**

ACC, anterior cingulate cortex; BGN, basal ganglia network; CAARMS, Comprehensive Assessment of At-Risk Mental States; FEP, first-episode psychosis; Ins, insula; MbThal, midbrain and thalamus; MTLN, medial temporal lobe network; NOI, network of interest; PANSS, positive and negative syndrome scale; SN, salience network; Str, striatum; tSNR, temporal signal-to-noise ratio; UHR, ultra-high risk.

### Supplementary figure 3. Effect of comorbidity on correlational analyses





The cluster value of the hippocampus of the MTLN showed a trend-level interaction between comorbidity (41 without and six with comorbidity) and the PANSS positive score ( $p = 0.08$ , corrected for contrast). The PANSS scores and connectivity values were controlled for age, sex, and tSNR.

#### Abbreviations



FEP, first-episode psychosis; MTLN, medial temporal lobe network; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal-to-noise ratio.

### Supplemental Figure 4. Effects of smoking on the correlational analyses

a)



b)



Information on smoking was available from the IoPPN, JHU, Kyoto, OSK, and Tokyo sites.

a) The cluster value of the hippocampus of the MTLN showed a trend-level interaction between smoking (54 non-smokers and 15 smokers) and the PANSS positive scale ( $p = 0.07$ , corrected for contrast). The PANSS scores and connectivity values were controlled for age, sex, and tSNR.

b) The connectivity between the MTLN and BGN-MbThal showed a trend-level interaction between smoking and the PANSS positive scale ( $p = 0.05$ , corrected for contrast).

**Abbreviations**

FEP, first-episode psychosis; MTLN, medial temporal lobe network; PANSS, Positive and Negative Syndrome Scale; tSNR, temporal signal-to-noise ratio.

## Supplementary Figure 5. All 62 components of the example subject



After ICA was applied to the rsfMRI data, independent components (ICs) were classified as noise based on 1) high-frequency power ratio (HF), 2) non-gray matter involvement index (NB), and 3) slice dependency index (SL). The ICs surrounded by blue frames are neuronal components, and the

ICs with yellow frames are noise components. The numbers indicate the ranks among all 62 ICs, with smaller ranks indicating better quality. Red ranks indicate noise classification.